SANES

9.599

+0.57%↑

BBVA

18.975

+0.08%↑

ALV

379.3

-0.42%↓

MUV2

546

+0.92%↑

INGA

22.965

-0.67%↓

SANES

9.599

+0.57%↑

BBVA

18.975

+0.08%↑

ALV

379.3

-0.42%↓

MUV2

546

+0.92%↑

INGA

22.965

-0.67%↓

SANES

9.599

+0.57%↑

BBVA

18.975

+0.08%↑

ALV

379.3

-0.42%↓

MUV2

546

+0.92%↑

INGA

22.965

-0.67%↓

SANES

9.599

+0.57%↑

BBVA

18.975

+0.08%↑

ALV

379.3

-0.42%↓

MUV2

546

+0.92%↑

INGA

22.965

-0.67%↓

SANES

9.599

+0.57%↑

BBVA

18.975

+0.08%↑

ALV

379.3

-0.42%↓

MUV2

546

+0.92%↑

INGA

22.965

-0.67%↓

Home・Akcijų sąrašas・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

210 1.2

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

207.2

Max

214.5

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-23M 93M
Pardavimai	400K 745M
P/E Sektoriaus vid.	78.044 30.097
Pelnas, tenkantis vienai akcijai	0.94
Pelno marža	12.43
Darbuotojai	10,134
EBITDA	-55M 201M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+10.43% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	729M 21B
Ankstesnė atidarymo kaina	208.8
Ankstesnė uždarymo kaina	210

Naujienos nuotaikos

By Acuity

29%

71%

76 / 528 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

202.7 / 211.7 Palaikymas ir pasipriešinimas

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-09 22:13; UTC

Uždarbis

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

2025-12-09 21:40; UTC

Uždarbis

GameStop Sales Fall as Collectibles Remain Only Bright Spot

2025-12-09 18:51; UTC

Įsigijimai, susijungimai, perėmimai

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

2025-12-09 16:57; UTC

Pagrindinės rinkos jėgos

Clear Secure Rises on Medicare Identity Verification Contract

2025-12-09 23:46; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

2025-12-09 23:46; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings Stake in Lenovo Now at 32.34%

2025-12-09 23:45; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

2025-12-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

2025-12-09 23:43; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

2025-12-09 23:43; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

2025-12-09 23:35; UTC

Rinkos pokalbiai

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025-12-09 22:42; UTC

Uždarbis

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

2025-12-09 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-12-09 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-09 21:48; UTC

Rinkos pokalbiai

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

2025-12-09 20:28; UTC

Rinkos pokalbiai

Oil Futures Decline for Second Straight Session -- Market Talk

2025-12-09 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

2025-12-09 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Teck Reports Voting Results From Special Meeting of Hldrs

2025-12-09 20:26; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

2025-12-09 20:21; UTC

Rinkos pokalbiai

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

2025-12-09 19:52; UTC

Uždarbis

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

2025-12-09 19:17; UTC

Uždarbis

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

2025-12-09 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-09 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-12-09 17:11; UTC

Uždarbis

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

10.43% į viršų

12 mėnesių prognozė

Vidutinis 233.57 EUR 10.43%

Aukščiausias 260 EUR

Žemiausias 210 EUR

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Sartorius Stedim Biotech. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

76 / 528 reitingas Finansų sektorius

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.